1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Dulaza Sold - Good Luck!

Discussion in 'New Haven Pharmaceuticals' started by anonymous, Feb 10, 2017 at 11:51 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Espero Acquires DURLAZA® (aspirin) Extended Release Capsules 
for Secondary Prevention of Stroke and Acute Cardiac Events
    February 7, 2017/ Press Release

    JACKSONVILLE, Fla. (February 7, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, today announced that the company has acquired the global rights to DURLAZA® (aspirin) Extended Release Capsules.Company officials will provide an update on February 13, 2017 at the BIO CEO & Investor Conference held at the Waldorf Astoria New York. DURLAZA is an FDA-approved and commercially available prescription 24-hour extended-release aspirin capsule, the first and only once-daily drug of its kind, indicated for the secondary treatment of stroke and acute cardiac events. Approved in September 2015, DURLAZA is designed to reduce the risk of death and myocardial infarction in patients with chronic coronary artery disease, and reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack (TIA). www.durlaza.com
     

  2. anonymous

    anonymous Guest

    I just sent my expense report to Patrick Clousoo!
     
  3. anonymous

    anonymous Guest

    THE WOODLANDS, Texas, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski is leaving his position as President and Chief Executive Officer and member of the Board of Directors to pursue other interests. Larry Dillaha, M.D., Chief Executive Officer of CavtheRx, was appointed interim President and Chief Executive Officer of the Company, effective immediately.

    “As Repros continues to advance its pipeline, the board will be conducting a search for a CEO with the appropriate experience to lead the Company’s next stage of growth,” said Patrick Fourteau, Chairman of the Company’s Board. “We’re grateful for Joe’s many years of dedication to Repros and wish him every success in his future endeavors.”

    Prior to becoming CEO of CavtheRx, Dr. Dillaha was Chief Operating Officer and Chief Medical Officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. He also served as Chief Medical Officer of Insys Therapeutics, Sciele Pharma and as Medical Director of Sanofi-Sythelabo. Dr. Dillaha received an M.D. degree from the University of Tennessee, Memphis.
     
  4. anonymous

    anonymous Guest

    What a bunch of douche bags! !!! What a shit drug and another scam. .​
     
  5. anonymous

    anonymous Guest

    Larry Dillaha is a tool !!!!!!